Cancer Vaccine is medicinal agent which can be utilized to elicit a natural immune response by enhancing T cell responses or increasing antibody production. With breath of experience and knowledge in the area of cancer vaccine, Creative Biolabs is dedicated to helping our clients successfully initiate and complete critical phases of cancer vaccine product discovery and development. Now we provide engineered human primary blood dendritic cells to induce antitumor cytotoxic lymphocytes to facilitate your immunotherapy projects.
As one of the current most popular immunotherapies, dendritic cell-based immunotherapy has shown its strength by boosting the patients’ own immune system to destroy cancer. DC-based immunotherapy has achieved significant clinical benefits, while some technical hurdles (including DC preparation, activation, cancer/testis antigen delivery) exist which limit its broad applications. Long Wu’s team has reported an influential study about “induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells”. They reported the development of immortalized and constitutively activated human primary blood dendritic cell lines (ihv-DCs). ihv-DCs can induce the generation of CTA-specific cytotoxic T lymphocytes (CTLs). These cytotoxic lymphocytes show the efficacy of lung metastasis suppression in NSG mice (see Fig.1). This approach can facilitate the development of cell-based immunotherapy to treat lung cancer.
Fig.1 Suppression of metastatic lung cancer by ihv-DC1.2-MAGEA3-primed cytotoxic lymphocytes in NSG mice. (Wu, 2018)
Inspired by this approach, our scientists developed a series of assays to facilitate your dendritic cell-based immunotherapy projects. Any individual module or integrated solution are all available.
This approach shows several major significances as follows:
It’s important for you to collaborate with a reliable and experienced partner to provide insights and suggestions, guide the right choice, eliminate the unsuccessful programs as early as possible. With our knowledge of dendritic cell and cancer vaccine, Creative Biolabs can assist in selecting the most promising candidate and guide our clients to develop better dendritic cell-based immunotherapies.
With rich laboratory capabilities and extensive immunotherapy experience, Creative Biolabs is fully confident in compliant data delivery within the desired timelines, and our client-focused, collaborative approach will ensure our clients can return us their additional needs at any stage without any hesitation. If you are interested in our services, please don’t hesitate to contact us to learn how we can be involved in your project.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE